Pharmaceutical Monitoring of Immunohepatitis Caused by PD-L1 Inhibitor: a Case Study

doi:10.19803/j.1672-8629.2021.07.21

Abstract

Abstract: Objective To explore the role of clinical pharmacists in the treatment of adverse drug reactions induced by PD-L1 inhibitors. Methods Related literature and guidelines were reviewed, while pharmaceutical recommendations and care were given by clinical pharmacists in response to adverse reactions induced after treatment of immune hepatitis with PD-L1 inhibitors (durvalumab). Results Adverse reactions were assessed by clinical pharmacists, who offered an effective and feasible treatment program so that the patient got better after treatment with hormones and immunosuppressive agents. Conclusion Clinical pharmacists should be alert to immune-related adverse reactions of PD-L1 inhibitors and help physicians to ensure the safety of clinical medication.

Key words: PD-L1 inhibitors, immune hepatitis, case study

CLC Number:

R975.5

WANG Xiaoxiao, CHEN Wanyi. Pharmaceutical Monitoring of Immunohepatitis Caused by PD-L1 Inhibitor: a Case Study[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 693-696.

References

[1] Suzman DL, Pelosof L, Rosenberg A, et al.Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents[J]. Liver, 2018, 38(6):976-987.
[2] Wang XX, Chen WY.PD-1/PD-L1 inhibitors associated with myocarditis-signal mining based on the three international spontaneous reporting systems in real world[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(11): 1404-1408.
[3] Chae YK, Arya A, Iams W, et al.Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)[J]. Journal for Immunotherapy of Cancer, 2018, 6(1): 39.
[4] Naidoo J, Page DB, Li BT, et al.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2016, 27(7): 1362.
[5] Yang JQ, He XJ, Lv Q, et al.Management of adverse events in cancer patients treated with PD-1/PD-L1 blockade: focus on Asian populations[J]. Frontiers in Pharmacology, 2019, 10(726): 1-16.
[6] Mcguire HM, Shklovskaya E, Edwards J, et al.Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report[J]. Cancer Immunology, Immunotherapy, CII, 2018, 67(4): 563-573.
[7] Kothapalli A, Khattak MA.Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series[J]. Melanoma Research, 2018, 28(2): 155-158.
[8] Li HY, Yang CP. Jin HT.Recent research progress in mechanism of liver injury induced by common drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(12): 750-756.
[9] Shi XM, Hu YL, Liang YL, et al.Clinical pharmacy service mode and its effect on patients with liver dysfunction[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(5): 286-290.
[10] Shao J, Wang C, Ren P, et al.Treatment and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer[J]. Bioscience Reports, 2020, 40(5): 1-11.
[11] Darnell EP, Mooradian MJ, Baruch EN, et al.Immune-related adverse events (iraes): diagnosis, management, and clinical pearls[J]. Current Oncology Reports, 2020, 22(4): 39.
[12] Inamori O, Miyagawa-Hayashino A, Ueno A, et al.Fulminant hepatitis as an immune-related adverse event after nivolumab treatment[J]. Pathology International, 2019, 69(7): 434-436.
[13] Ricciuti B, Genova C, De Giglio A, et al.Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: Long-term outcomes from a multi-institutional analysis[J]. J Cancer Res Clin Oncol, 2019, 145(2): 479-485.
[14] Yang H, Yin DH.Pharmaceutical practice of one case of severe hypokalemia induced by glucocorticoid in patient with minimal change nephropathy[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2019,16(7):425-429.
[15] Wen K, Tong YL, Cai Y, et al.Bibliometric analysis of immune-related adverse events caused by PD-1/PD-L1 inhibitors[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(15): 1907-1912.